The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10240 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether

Not Open Access | Intravenous β-artemether formulation (ARM NLC) as a superior alternative to commercial artesunate formulation

October 12, 2012 - 16:48 -- Patrick Sampao
Author(s): 
Sushant Patil, Medha Joshi, Sulabha Pathak, Shobhona Sharma and Vandana Patravale
Reference: 
Journal of Antimicrobial Chemotherapy, Volume 67, Issue 11 Pp. 2713-2716

MalariaWorldThe study compared the in vivo pharmacodynamic efficacy of ARM NLC with C-AST in a murine model. For this study, the Peters 4 day suppressive test was adopted. Plasmodium berghei was the causative organism for inducing malaria in mice.

Medical Treatment: 

Not Open Access | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

August 15, 2012 - 09:51 -- Patrick Sampao
Author(s): 
Pauline Byakika-Kibwika, Mohammed Lamorde, Concepta Merry, et al.
Reference: 
J. Antimicrob. Chemother. (2012) 67 (9): 2213-2221

MalariaWorldWe investigated drug–drug interactions between artemether/lumefantrine and efavirenz or nevirapine.

Person: 
Country: 
Medical Treatment: 

NOT Open Access | The Spiroindolone Drug Candidate NITD609 Potently Inhibits Gametocytogenesis and Blocks Plasmodium falciparum Transmission to Anopheles Mosquito Vector

June 20, 2012 - 08:50 -- Kabogo Ndegwa
Author(s): 
J. C. van Pelt-Koops, H. E. Pett, W. Graumans, M. van der Vegte-Bolmer, G. J. van Gemert, M. Rottmann, B. K. S. Yeung, T. T. Diagana, and R. W. Sauerwein
Reference: 
Antimicrob. Agents Chemother. July 2012 vol. 56 no. 7 3544-3548

MalariaWorldThe global malaria agenda has undergone a reorientation from control of clinical cases to entirely eradicating malaria.

Open Access | Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with Plasmodium falciparum infections

May 2, 2012 - 14:27 -- Kabogo Ndegwa
Author(s): 
Pillai DR, Lau R, Khairnar K, Lepore R, Via A, Staines HM, Krishna S
Reference: 
Malaria Journal 2012, 11:131 (27 April 2012)

MalariaWorldThese findings were further explored in molecular modelling experiments that suggest mutations in pfatp6 are unlikely to affect differential binding of artemisinins at their proposed site, whereas there may be differences in such binding associated with mutations in pfmdr1.

Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults

April 10, 2012 - 14:59 -- Patrick Sampao
Author(s): 
Pauline Byakika-Kibwika, Mohammed Lamorde, Concepta Merry, et al.
Reference: 
J. Antimicrob. Chemother. (2012) 67 (5): 1217-1223.

MalariaWorldWe investigated the pharmacokinetics of artemether, dihydroartemisinin and lumefantrine after administration of a single dose of 80/480 mg of artemether/lumefantrine to HIV-infected adults, taken with and without lopinavir/ritonavir.

Country: 
Medical Condition: 
Medical Treatment: 

Short Report: Successful Oral Therapy for Severe Falciparum Malaria: The World Health Organization Criteria Revisited

March 9, 2012 - 13:34 -- Patrick Sampao
Author(s): 
Eran Kopel, Enbal Marhoom, Yechezkel Sidi and Eli Schwartz
Reference: 
Am J Trop Med Hyg 2012 86:409-411

MalariaWorldWe report a successful treatment of severe falciparum malaria in a non-immune adult patient with 30% parasitemia treated with the 6-dose oral regimen of artemether plus lumefantrine combination therapy alone.

Medical Condition: 
Medical Treatment: 

Population Pharmacokinetics of Artemether, Lumefantrine, and Their Respective Metabolites in Papua New Guinean Children with Uncomplicated Malaria

October 17, 2011 - 10:24 -- Kabogo Ndegwa
Author(s): 
Sam Salman, Madhu Page-Sharp, Susan Griffin, Kaye Kose, Peter M. Siba, Kenneth F. Ilett, Ivo Mueller, and Timothy M. E. Davis
Reference: 
Antimicrobial Agents and Chemotherapy, November 2011,p. 5306-5313, Vol. 55, No. 11

MalariaWorldThere are sparse published data relating to the pharmacokinetic properties of artemether, lumefantrine, and their active metabolites in children, especially desbutyl-lumefantrine.

Medical Condition: 
Medical Treatment: 

Artemether and Artesunate Show the Highest Efficacies in Rescuing Mice with Late-Stage Cerebral Malaria and Rapidly Decrease Leukocyte Accumulation in the Brain

March 22, 2011 - 11:55 -- Kabogo Ndegwa
Author(s): 
L. Clemmer, Y. C. Martins, G. M. Zanini, J. A. Frangos, and L. J. M. Carvalho
Reference: 
Antimicrobial Agents and Chemotherapy, April 2011, p. 1383-1390, Vol. 55, No. 4

The murine model of cerebral malaria (ECM) caused by Plasmodium berghei ANKA (PbA) infection in susceptible mice has been extensively used for studies of pathogenesis and identification of potential targets for human CM therapeutics.

Medical Condition: 
Medical Treatment: 

Pharmacology: Population Pharmacokinetics and Pharmacodynamics of Artemether and Lumefantrine during Combination Treatment in Children with Uncomplicated Falciparum Malaria in Tanzania

October 18, 2010 - 09:40 -- Patrick Sampao
Author(s): 
Sofia F., Andreas M., et al.
Reference: 
Antimicrob. Agents Chemother., Nov 2010; 54: 4780 - 4788.

The aim of this analysis was to describe the pharmacokinetics and pharmacodynamics of artemether, dihydroartemisinin, and lumefantrine in African children with uncomplicated malaria.

Person: 
Medical Condition: 
Medical Treatment: 

Open Access | Research: Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria

April 16, 2010 - 08:29 -- Kabogo Ndegwa
Author(s): 
Phu NH, Tuan PQ, Day N, Mai NT, Chau TT, Chuong LV, Sinh DX, White NJ, Farrar J, Tran HT
Reference: 
Malaria Journal 2010, 9:97 (15 April 2010)

Both artemether and artesunate have been shown to be superior to quinine for the treatment of severe falciparum malaria in Southeast Asian adults, although the magnitude of the superiority has been greater for artesunate than artemether. These two artemisinin derivatives had not been compared in a randomized trial.

Technology: 
Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - artemether